By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider and middlemen involved.

Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells. Experts say it offers improved outcomes in several advanced cancers and ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

In a yearlong investigation led by the International Consortium of Investigative Journalists, reporters from more than 37 ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, Germany’s Merck KGaA and Japan's Ono Pharmaceutical for an experimental ...